The disputed patents cover Yutrepia’s use to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD), which constitutes about half of the inhaled treprostinil market. Liquidia intends to appeal the decision and has asked the FDA to remove only the PH-ILD indication to keep the drug's pulmonary arterial hypertension (PAH) business intact. Despite the legal uncertainty, Needham cut its price target from $110 to $70, assuming Yutrepia stays on the market but pays a 50% royalty on PH-ILD revenue. Judge Andrews has given both parties one week to submit a proposed final judgment on the remedy.
Wednesday, October 21, 2026
Story
United Therapeutics Pushes to Pull Yutrepia Off Market Entirely
Business20 days ago
Liquidia shares fell to around $25.32 in pre-market trading on Oct. 1 as a legal battle intensified over whether its flagship drug, Yutrepia, can remain available to patients. United Therapeutics is now pushing a Delaware court to order the complete withdrawal of Yutrepia's New Drug Application, a more aggressive move than previously seeking only an injunction. This follows a ruling that two of six patent claims asserted by United Therapeutics were valid and infringed, wiping roughly $3.6B in market value from Liquidia after its stock plunged 57% on Sept. 30.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.